Saturday 17 October 2026 Export SUPN’s income statement to Excel — free account

Supernus Pharmaceuticals, Inc.

SUPN Healthcare Drug Manufacturers Specialty & Generic

Supernus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.0 million, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 32.4%, EPS fell 352.5% and free cash flow fell 109.3%, each against the same quarter a year earlier.

37.88 1.69 −4.27%

Follow SUPN

Alert me

Market cap: $2.3B
P/E: 0.0×
Fwd P/E: 103×
Dividend yield: —
F-score: 5/9
Altman Z: 5.41
Beneish M: −2.54
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Supernus Pharmaceuticals, Inc. (SUPN) P/E ratio

Alert me on P/E ratio

Supernus Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1,418× (March 2024) — the current reading is the lowest in ten years.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/SUPN/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Supernus Pharmaceuticals, Inc. P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/SUPN/metrics/pe-ratio">Supernus Pharmaceuticals, Inc. (SUPN) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	0.0×	—
FY2024	26.9×	(97.59%)
FY2023	1,118×	3,272.04%
FY2022	33.2×	15.99%
FY2021	28.6×	173.84%
FY2020	10.4×	(5.37%)
FY2019	11.0×	(28.93%)
FY2018	15.5×	(56.63%)
FY2017	35.8×	153.82%
FY2016	14.1×	(69.57%)

Period	P/E ratio	Change
Jun 2026	0.0×	—
Mar 2026	0.0×	—
Dec 2025	0.0×	—
Sep 2025	0.0×	—
42 more quarters	Free account

Against its own ten years

Low 0.0× High 1,418×

Ten-year median 21.2×

Current reading's percentile 11

Company	P/E ratio
XERS Xeris Biopharma Holdings, Inc. compare	n/m
PRGO Perrigo Company plc compare	n/m
BCRX BioCryst Pharmaceuticals, Inc. compare	n/m
ALVO Alvotech compare	n/m
SUPN Supernus Pharmaceuticals, Inc.	n/m
HCM HUTCHMED (China) Limited Sponsored ADR compare	n/m
PBH Prestige Consumer Healthcare Inc. compare	13.9×
ANIP ANI Pharmaceuticals, Inc. compare	14.9×
LQDA Liquidia Corporation compare	21.9×
Drug Manufacturers Specialty & Generic industry median	19.2×
Healthcare sector median	23.0×
Market median	18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Supernus Pharmaceuticals, Inc. (SUPN) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on SUPN

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on SUPN

Stockrow Weekly